Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DEAD-box helicase 43 pseudogene 2 (DDX43P2) is named as a pseudogene related to the protein-coding DEAD-box helicase 43 (DDX43), but there is no evidence that DDX43P2 encodes a functional protein or that it serves as a therapeutic target. Pseudogenes, by definition, are genomic DNA sequences similar to normal genes but are non-functional; they typically arise from the duplication or retrotransposition of functional genes and are generally not translated into proteins. Context and supporting details: - DDX43 (not DDX43P2) is a protein-coding gene known to encode an ATP-dependent RNA and DNA helicase, implicated in several biological functions and considered as a cancer/testis antigen and potential cancer therapy target[1]. - DEAD-box protein family includes enzymes involved in RNA metabolism, but only functional protein-coding members (such as DDX43 itself) are of interest as molecular targets, not their pseudogenes[2]. - No evidence supports the role of DDX43P2 pseudogene in disease, cell signaling, or as a receptor, enzyme, transporter, or any other classical therapeutic target class. If you meant the functional protein DDX43 (also known as HAGE), that is a valid cancer biomarker and potential therapeutic target, but DDX43P2 only annotates its related pseudogene, which is not considered a therapeutic target by itself[1]. There is no information in the current literature or standard gene/protein databases to suggest DDX43P2 encodes a receptor, enzyme, or functional protein, nor any associated drugs, biomarkers, or disease roles. If your intent was to query the functional gene or its encoded protein (DDX43/HAGE), please clarify, as the answer would be different and substantially richer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DEAD-box helicase 43 pseudogene 2 (DDX43P2).